2009 Access Clinical Trials Data 
Cannabis Law Report
APRIL 8, 2022
This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.
The Cannigma
JULY 1, 2022
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 6, 2021
He was also listed in “Best Doctors in America” in 2007, 2009, and 2010. We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.” In 2019, Dr. Johnson received the R. ” About Ehave, Inc. Ehave, Inc.
TheAnswerPage
JANUARY 11, 2022
As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Available at: [link] Accessed 05 Dec. link] -Accessed December 5, 2021.
The Cannigma
JANUARY 13, 2023
A review of existing endocannabinoid system and migraine research from March 2022 identified many surveys, but fewer clinical research trials, and even fewer double-blind placebo studies. Topical cannabis products can also be useful, but research and data is very limited.
Cannabis Law Report
OCTOBER 29, 2019
The PK data on cats shows there are differences in absorption between cats and dogs and that dosing may be different between these two species and that our chew form is likely to be more absorbable than oils in general. This data gives us confidence in the use of both the chew and the oils as effective means for delivering CBD to your pet.”.
Cannabis Law Report
NOVEMBER 24, 2021
However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. At the same time, the outlook on cannabis research data is largely positive. Refractory paediatric epilepsy.
Expert insights. Personalized for you.
52 
Let's personalize your content